Discovery explains how the chickenpox and shingles virus remains dormant

April 16, 2018, University College London
Electron micrograph of a varicella zoster virus. Credit: Centre for Disease Control/Dr. Erskine Palmer/B.G. Partin, Source: Public Health Image Library

A research team led by UCL and Erasmus University has found a missing piece to the puzzle of why the virus that causes chickenpox and shingles can remain dormant for decades in human cells.

Described in a recent paper in Nature Communications, researchers discovered there is an RNA transcript in the (VZV), that continues to remain active after a person has recovered from chickenpox.

Most adults worldwide are infected with VZV, which stays dormant after chickenpox has cleared, but can reactivate later in life – in about 30% of people – as shingles, which causes both a painful rash and the potential for more serious complications including debilitating pain, blindness or a stroke.

"It's been more than 30 years since VZV latency in human nerve cells was first described, and ever since then, researchers have been trying to identify the factor that causes the virus to remain latent. Our discovery provides an important step forward towards control of this virus," said the study's lead author, Professor Judith Breuer (UCL Infection & Immunity).

Previous studies were unable to identify how VZV latency works, partly because, unlike the herpes simplex viruses, which are also alphaherpesviruses that remains dormant after initial infection, there are no animal models of VZV latency.

To overcome this challenge, the researchers developed a new technique using human neurons that were obtained very quickly after the patients had died (6 hours on average), when previous studies had shown that fewer post mortem changes had occurred in the tissues.

Of the 18 donors, the neurons of 13 of them were infected with both herpes simplex and VZV, enabling the researchers to compare their findings against the better-understood model of herpes simplex.

The researchers extracted nucleic acid from the neurons and sequenced the RNA, comparing it with models of the VZV genome. They found that only one VZV RNA transcript was detectable in all the neurons, which they called the latency-associated transcript. The researchers also confirmed that only one herpes simplex transcript is detectable when dormant, something that has been queried in the past.

They supported their findings by infecting cells in the lab with VZV and found that the latency-associated transcript inhibits the expression of a gene that is critical to viral replication, suggesting that the transcript may play a key role in determining whether the is actively replicating or remaining dormant.

"Our findings are now helping us understand how VZV can remain dormant for so long. Further research will tell us more about how exactly this RNA transcript works, and what happens differently when VZV reactivates later in life to cause shingles.

"We hope our discovery can help the eventual development of a new, improved vaccine that instead of causing dormancy, entirely prevents VZV infection," said the study's first author, Dr. Daniel Depledge, who conducted the research at UCL before moving to New York University.

The researchers say their discovery was made possible by a combination of high quality human clinical specimens from the Netherlands Brain Bank and specialised highly sensitive molecular detection technologies developed at UCL.

Explore further: After infection, herpes lurks in nerve cells, ready to strike—New research reveals what enables the virus to do so

More information: Daniel P. Depledge et al. A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61, Nature Communications (2018). DOI: 10.1038/s41467-018-03569-2

Related Stories

After infection, herpes lurks in nerve cells, ready to strike—New research reveals what enables the virus to do so

March 15, 2018
Once herpes simplex infects a person, the virus goes into hiding inside nerve cells, hibernating there for life, periodically waking up from its sleep to reignite infection, causing cold sores or genital lesions to recur.

Chicken pox vaccine linked with shingles at the vaccination site in some children

February 9, 2018
New research in Pediatric Dermatology reports several cases of shingles that developed at the original vaccination site in healthy children after they were immunized against chicken pox. Most of these cases were initially ...

Shot may protgect against shingles

February 19, 2018
Anyone who has had chickenpox or the chickenpox vaccine is at risk for the painful skin condition herpes zoster, more commonly known as shingles. Both diseases are caused by the varicella-zoster virus, which stays in the ...

Identifying underlying causes of immune deficiencies that increase shingles risk

June 12, 2017
Early life infections with varicella zoster virus cause chickenpox, but the virus can remain dormant in the nervous system for decades and reactivate to cause herpes zoster, commonly known as shingles. Shingles is characterized ...

Herpes virus mutant points towards new vaccine strategy

December 19, 2017
A Northwestern Medicine study published in PLOS Pathogens describes a newly-designed mutant herpes virus called R2 that provides a strategy for the development of novel herpes virus vaccines.

Scientists advance understanding of herpesvirus infection

April 12, 2017
Herpes simplex virus (HSV) infections last a lifetime. Once a person has been infected, the virus can remain dormant (latent) for years before periodically reactivating to cause recurrent disease. This poorly understood cycle ...

Recommended for you

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.